SCHEDULE: Farallon Group Amends Beta Bionics Stake Disclosure
Beneficial Ownership Amendment
Farallon Capital Management and related entities update their Schedule 13G filing for Beta Bionics, Inc., reflecting internal management changes and associated beneficial ownership adjustments.
Summary
- Farallon Capital Management, L.L.C. and its affiliated entities, including Zone Healthcare Holdings, LLC, collectively report beneficial ownership in Beta Bionics, Inc. Common Stock.
- Zone Healthcare Holdings, LLC and Farallon Capital Management, L.L.C. each beneficially own 3,277,220 shares, representing 7.4% of the class.
- Farallon Partners, L.L.C. beneficially owns 1,060,139 shares, representing 2.4% of the class.
- Several Farallon Individual Reporting Persons, including Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Varun N. Gehani, Nicolas Giauque, Avner A. Husen, David T. Kim, Michael G. Linn, Patrick (Cheng) Luo, Thomas G. Roberts, Jr., Edric C. Saito, Daniel S. Short, Andrew J. M. Spokes, John R. Warren, and Mark C. Wehrly, are each deemed beneficial owners of 4,379,920 shares, representing 9.9% of the class, due to their roles in managing the investment entities.
- The filing is an Amendment No. 3 to Schedule 13G, primarily to report changes in the individuals associated with the beneficial ownership within the Farallon group.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. It is a standard regulatory update reflecting internal personnel changes within a significant institutional investor group, rather than a direct commentary on the issuer's performance or prospects.
Positives
- The continued significant beneficial ownership by Farallon Capital Management and its affiliates indicates ongoing investment interest in Beta Bionics, Inc.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive institutional investors, providing transparency into significant ownership stakes. The internal management changes within Farallon Capital Management reflect typical operational adjustments within large investment firms and do not inherently signal a change in investment strategy towards Beta Bionics, Inc. or broader industry trends.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Managing Member/Manager of Farallon entities | NA | Avner A. Husen | 01/01/2026 | Became a member/manager of Farallon Capital Management, L.L.C., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., and Farallon F5 (GP), L.L.C., leading to deemed beneficial ownership of Beta Bionics shares. |
| Managing Member/Manager of Farallon entities | Richard B. Fried | NA | 12/31/2025 | Ceased to be a member/manager of Farallon Capital Management, L.L.C., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., and Farallon F5 (GP), L.L.C., and is no longer deemed a beneficial owner of Beta Bionics shares. |
| Managing Member/Manager of Farallon entities | Rajiv A. Patel | NA | 12/31/2025 | Ceased to be a member/manager of Farallon Capital Management, L.L.C., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., and Farallon F5 (GP), L.L.C., and is no longer deemed a beneficial owner of Beta Bionics shares. |
| Managing Member/Manager of Farallon entities | William Seybold | NA | 12/31/2025 | Ceased to be a member/manager of Farallon Capital Management, L.L.C., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., and Farallon F5 (GP), L.L.C., and is no longer deemed a beneficial owner of Beta Bionics shares. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Management Structure | Avner A. Husen joined as a managing member/manager across various Farallon entities (Management Company, Farallon General Partner, FCIP V General Partner, F5MI General Partner). | 01/01/2026 | Reflects internal personnel changes within the investment group, impacting who is deemed a beneficial owner of Beta Bionics shares through their control over the investment entities. |
| Internal Management Structure | Richard B. Fried, Rajiv A. Patel, and William Seybold ceased their roles as managing members/managers across various Farallon entities. | 12/31/2025 | Reflects internal personnel changes within the investment group, meaning these individuals are no longer deemed beneficial owners of Beta Bionics shares through their control over the investment entities. |
Stakeholder Impact
- Shareholders: Provides updated transparency on the beneficial ownership structure of a significant institutional investor.
- Management: Awareness of the individuals within the Farallon group who hold investment discretion over a substantial stake.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Richard B. Fried, Rajiv A. Patel, and William Seybold ceased to be members/managers of Farallon entities and beneficial owners. |
| 01/01/2026 | Avner A. Husen became a member/manager of Farallon entities and a beneficial owner. |
| 02/09/2026 | Date of signing of the Schedule 13G Amendment. |
Keywords
Beta Bionics, Farallon Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management, Shareholder Disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.